Anbio Biotechnology

NNNN

Company Profile

  • Business description

    Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).

  • Contact

    Friedrich-Ebert-Anlage 35-37
    Frankfurt am MainHE60327
    DEU

    T: +49 69870039170

    https://www.anbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Instruments & Supplies

    Fiscal Year End

    31 December 2026

    Employees

    27

Stocks News & Analysis

stocks

After plunge ASX blue chip undervalued

This company earns a moat from our analysts.
stocks

Older cohorts the budget losers, not necessarily the ASX listed insurers

Proposed legislation removes health insurance rebates.
stocks

Turnaround progressing for ASX share

Margins have rebased by shares are undervalued.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,829.5017.300.20%
CAC 407,981.765.73-0.07%
DAX 4024,400.6592.730.38%
Dow JONES (US)49,501.07185.05-0.37%
FTSE 10010,330.556.800.07%
HKSE25,797.85122.670.48%
NASDAQ25,890.54200.20-0.77%
Nikkei 22560,550.59265.36-0.44%
NZX 50 Index12,974.32211.401.66%
S&P 5007,367.9535.10-0.47%
S&P/ASX 2008,604.7023.100.27%
SSE Composite Index4,169.5438.010.92%

Market Movers